Disease Burden Associated with All Infants in Their First RSV Season in the UK: A Static Model of Universal Immunization with Nirsevimab Against RSV-Related Outcomes
Abstract Introduction Respiratory syncytial virus (RSV) leads to significant morbidity in newborn infants in the United Kingdom (UK). Nirsevimab, a long-acting monoclonal antibody, received approval from the European Medicines Agency and has been licensed by the Medicines and Healthcare products Reg...
Guardat en:
| Autors principals: | , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Adis, Springer Healthcare
2024-09-01
|
| Col·lecció: | Infectious Diseases and Therapy |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1007/s40121-024-01037-7 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|